← Leaderboards
Steven A Webber
University Of Pittsburgh At Pittsburgh
$15,503,800
Attributed
$16,364,700
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.4M · FY2005–23$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$28,566,773 · 8
By mechanism
P50$13,556,204 · 3
U01$10,680,179 · 2
K12$2,608,589 · 1
R38$1,721,801 · 2
Top collaborators
- Christopher S. Williams5 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Oscar L. Lopez$26,660,804
- Joseph A. Carcillo$10,929,314
- Susan Manzi$6,430,165
- Daniel S McConnell$24,789,449
- Dana Young Fuhrman$1,151,344
Others in their field
Top investigators on “Childhood”
- Gregory H Reaman · National Childhood Cancer Foundation$268,060,146
- Barbara Driver · Westat, Inc.$206,410,885
- Sharon A Nachman · Johns Hopkins University$191,166,598
- Peter C Adamson · National Childhood Cancer Foundation$190,988,407
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$187,267,729
- James E. Gern · University Of Wisconsin-Madison$149,875,125
Research focus
ChildhoodEvaluationAreaScientistResearch PersonnelHeart TransplantationBaseAllograftingAcuteProtocols DocumentationAntibodiesChronicChildTransplantationCollaborationsProgramsFacultyMentorsCareer DevelopmentEnvironmentMentorshipMedical SchoolsAptitudeCareer
Grant awards (37)
Vanderbilt Stimulating Access to Research in Residency (V-StARR)$378,886
R38 · FY2023 · HL · contact PI
Pathogenesis, Targeted Therapeutics, and New Vaccines for Childhood Disease$439,992
K12 · FY2022 · HD · contact PI
Pathogenesis, Targeted Therapeutics, and New Vaccines for Childhood Disease$439,992
K12 · FY2021 · HD · contact PI
Vanderbilt Stimulating Access to Research in Residency (V-StARR)$322,010
R38 · FY2021 · HL · contact PI
Pathogenesis, Targeted Therapeutics, and New Vaccines for Childhood Disease$345,721
K12 · FY2020 · HD · contact PI
Vanderbilt Stimulating Access to Research in Residency (V-StARR)$331,335
R38 · FY2020 · HL · contact PI
Pathogenesis, Targeted Therapeutics, and New Vaccines for Childhood Disease$345,721
K12 · FY2019 · HD · contact PI
Vanderbilt Stimulating Access to Research in Residency (V-StARR)$340,390
R38 · FY2019 · HL · contact PI
Chronic Graft Destruction: Interplay of Allo- and Autoantibodies and Nonadherence$396,354
U01 · FY2018 · AI · contact PI
Vanderbilt Stimulating Access to Research in Residency (V-StARR)$349,180
R38 · FY2018 · HL · contact PI
Pathogenesis, Targeted Therapeutics, and New Vaccines for Childhood Disease$345,721
K12 · FY2018 · HD · contact PI
Chronic Graft Destruction: Interplay of Allo- and Autoantibodies and Nonadherence$776,054
U01 · FY2017 · AI · contact PI
Pathogenesis, Targeted Therapeutics, and New Vaccines for Childhood Disease$345,721
K12 · FY2017 · HD · contact PI
Chronic Graft Destruction: Interplay of Allo- and Autoantibodies and Nonadherence$670,207
U01 · FY2016 · AI · contact PI
Pathogenesis, Targeted Therapeutics, and New Vaccines for Childhood Disease$259,291
K12 · FY2016 · HD · contact PI
Chronic Graft Destruction: Interplay of Allo- and Autoantibodies and Nonadherence$146,414
U01 · FY2016 · AI · contact PI
Pathogenesis, Targeted Therapeutics, and New Vaccines for Childhood Disease$86,430
K12 · FY2016 · HD · contact PI
Chronic Graft Destruction: Interplay of Allo- and Autoantibodies and Nonadherence$828,397
U01 · FY2015 · AI · contact PI
Chronic Graft Destruction: Interplay of Allo- and Autoantibodies and Nonadherence$845,537
U01 · FY2014 · AI · contact PI
Chronic Graft Destruction: Interplay of Allo- and Autoantibodies and Nonadherence$1,174,176
U01 · FY2013 · AI · contact PI
Alloantibodies in Cardiac Transplantation - Intervention, Outcomes and Mechanisms$593,180
U01 · FY2012 · AI · contact PI
Alloantibodies in Cardiac Transplantation - Intervention, Outcomes and Mechanisms$547,602
U01 · FY2012 · AI · contact PI
Alloantibodies in Cardiac Transplantation - Intervention, Outcomes and Mechanisms$1,136,831
U01 · FY2011 · AI · contact PI
Alloantibodies in Cardiac Transplantation - Intervention, Outcomes and Mechanisms$1,202,589
U01 · FY2010 · AI · contact PI
Alloantibodies in Cardiac Transplantation - Intervention, Outcomes and Mechanisms$1,210,936
U01 · FY2009 · AI · contact PI
Optimizing Outcome After Pediatric Heart Transplantation$2,032,609
P50 · FY2008 · HL · contact PI
Alloantibodies in Cardiac Transplantation - Intervention, Outcomes and Mechanisms$1,151,902
U01 · FY2008 · AI · contact PI
Thymic Tolerance in Pediatric Heart Transplantation$186,441
P50 · FY2008 · HL · contact PI
Optimizing Outcome After Pediatric Heart Transplantation$2,123,071
P50 · FY2007 · HL · contact PI
Thymic Tolerance in Pediatric Heart Transplantation$226,196
P50 · FY2007 · HL · contact PI
Optimizing Outcome After Pediatric Heart Transplantation$2,437,747
P50 · FY2006 · HL · contact PI
Thymic Tolerance in Pediatric Heart Transplantation$274,672
P50 · FY2006 · HL · contact PI
Optimizing Outcome After Pediatric Heart Transplantation$2,782,386
P50 · FY2005 · HL
Thymic Tolerance in Pediatric Heart Transplantation$266,672
P50 · FY2005 · HL
Optimizing Outcome After Pediatric Heart Transplantation$2,826,260
P50 · FY2004 · HL
Thymic Tolerance in Pediatric Heart Transplantation$259,267
P50 · FY2004 · HL
Core A--Administrative$140,883
P50 · FY2004 · HL